-
Media Release
New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
-
Media Release
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
-
Media Release
Alcon teams up with Venus Williams, tennis champion and dry eye sufferer, to launch Systane® Complete eye drops
-
Media Release
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
-
Media Release
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
-
Media Release
Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
-
Media Release
Novartis and Amgen announce FDA approval of Aimovig™ (erenumab-aooe), a novel treatment developed specifically for migraine prevention
-
Media Release
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
-
Media Release
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
-
Media Release
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
-
Media Release
Novartis and Amgen highlight findings from a large global patient survey revealing that worldwide approximately 60% of employed people with migraine missed, on average, a week of work in a month
-
Media Release
Novartis announces funding for patient advocacy initiatives to support and empower metastatic breast cancer community